Lipocine Inc (LPCN)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.45+1.24%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · LPCN
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -15.8% |
| Our one-year growth estimate | diamond | -24.1% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 8.3 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
LPCN — director transition
Dated 2026-08-03
Director — Michael Grissinger: Appointment of Michael Grissinger as a director with an initial stock option grant and annual retainer.
Why it matters: More money from TLANDO shows that the product is selling well.
Supportive ifRoyalty revenue from TLANDO exceeds $200,000 in the next quarter.
Worry ifRoyalty revenue from TLANDO drops or stays below $190,000.
Why it matters: The FDA meeting will clarify the path forward for LPCN 1154 after mixed Phase 3 results.
Watch forThe FDA provides positive feedback on the development path for LPCN 1154.
Also watch forThe FDA has big worries about LPCN 1154's development.
Why it matters: Showing data can change how investors see LPCN 1154.
Watch forLPCN 1154 data gets a good response at a big medical conference.
Also watch forNegative feedback or lack of interest in LPCN 1154 data at the conference.
Why it matters: Earnings results will show how the company is doing financially. A big loss could worry investors.
Worry ifQ2 net loss narrows compared to Q1.
Less concerning ifQ2 net loss widens compared to Q1.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$173 on $10,000 · ±1.7% | How much price usually moves either way. |
| Bad day | $519 loss on $10,000 · 5.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,277 loss on $10,000 · 82.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: A drop in cash reserves may mean financial trouble and affect operations.
Worry ifCash reserves remain above $23 million.
Less concerning ifCash reserves fall below $20 million.
Why it matters: Starting a new trial could strengthen the case for LPCN 1154 after the Phase 3 results.
Supportive ifThe company announces the start of a new placebo-controlled trial for LPCN 1154.
Worry ifNo announcement of a new trial or delays in starting the trial.
Why it matters: New trial results will show how well LPCN 1154 works and its safety.
Watch forA new trial shows a clear improvement in depression symptoms.
Also watch forThe new trial did not show a clear improvement in depression symptoms.
Why it matters: Better cash flow helps with money management. It also lowers losses.
Supportive ifCash flow from operations becomes positive for the first time in 2026.
Worry ifCash flow from operations is still negative for another quarter.
Why it matters: Changes in cash balance will show how well the company is doing financially.
Watch forCash balance rises a lot after the Q3 guidance meeting.
Also watch forCash balance decreases or remains flat after the Q3 guidance meeting.
Why it matters: If healthcare revenue growth speeds up, it may help Lipocine's market position.
Supportive ifHealthcare sector revenue growth exceeds 10% year over year.
Worry ifHealthcare revenue growth remains below 10% year over year.
Why it matters: Improved cash flow signals better financial health and can reduce operating losses. Investors will look for signs of recovery.
Supportive ifCash from operations is now positive. It is over $0 for the quarter.
Worry ifCash from operations is still negative. This continues the trend of losses.